StockMacro
Menu

Bio-Techne

$72.67 +51% in 6 monthsMarket cap $11.4B

TECH on XNAS, Health Care, Bio-Techne Corp., job postings

Measures activity, not value. Not investment advice.

Net income rose 121% to $172M while revenue grew 0.9% over the last 12 months.

  • GoodLatest quarter revenue rose 4.6% to $299.7M

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
3,000
Website
bio-techne.com
Listed
Nasdaq, US
Last results
12 Aug 2026
Next results
expected around 3 Feb 2027 (an estimate: a year ago it reported on 4 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $299.7M, net income $28.3M.
Quarter to 31 Dec 2021: revenue $269.3M, net income $80.2MQuarter to 31 Dec 2021: revenue $269.3M, net income $80.2MQuarter to 31 Mar 2022: revenue $290.4M, net income $60.7MQuarter to 31 Mar 2022: revenue $290.4M, net income $60.7MQuarter to 30 Jun 2022: revenue $288.2M, net income $61.5MQuarter to 30 Jun 2022: revenue $288.2M, net income $61.5MQuarter to 30 Sep 2022: revenue $269.7M, net income $89.6MQuarter to 30 Sep 2022: revenue $269.7M, net income $89.6MQuarter to 31 Dec 2022: revenue $271.6M, net income $50.0MQuarter to 31 Dec 2022: revenue $271.6M, net income $50.0MQuarter to 31 Mar 2023: revenue $294.1M, net income $70.2MQuarter to 31 Mar 2023: revenue $294.1M, net income $70.2MQuarter to 30 Jun 2023: revenue $301.3M, net income $75.5MQuarter to 30 Jun 2023: revenue $301.3M, net income $75.5MQuarter to 30 Sep 2023: revenue $276.9M, net income $51.0MQuarter to 30 Sep 2023: revenue $276.9M, net income $51.0MQuarter to 31 Dec 2023: revenue $272.6M, net income $27.5MQuarter to 31 Dec 2023: revenue $272.6M, net income $27.5MQuarter to 31 Mar 2024: revenue $303.4M, net income $49.1MQuarter to 31 Mar 2024: revenue $303.4M, net income $49.1MQuarter to 30 Jun 2024: revenue $306.1M, net income $40.6MQuarter to 30 Jun 2024: revenue $306.1M, net income $40.6MQuarter to 30 Sep 2024: revenue $289.5M, net income $33.6MQuarter to 30 Sep 2024: revenue $289.5M, net income $33.6MQuarter to 31 Dec 2024: revenue $297.0M, net income $34.9MQuarter to 31 Dec 2024: revenue $297.0M, net income $34.9MQuarter to 31 Mar 2025: revenue $316.2M, net income $22.6MQuarter to 31 Mar 2025: revenue $316.2M, net income $22.6MQuarter to 30 Jun 2025: revenue $317.0M, net income -$17.7MQuarter to 30 Jun 2025: revenue $317.0M, net income -$17.7MQuarter to 30 Sep 2025: revenue $286.6M, net income $38.2MQuarter to 30 Sep 2025: revenue $286.6M, net income $38.2MQuarter to 31 Dec 2025: revenue $295.9M, net income $38.0MQuarter to 31 Dec 2025: revenue $295.9M, net income $38.0MQuarter to 31 Mar 2026: revenue $311.4M, net income $51.0MQuarter to 31 Mar 2026: revenue $311.4M, net income $51.0MQuarter to 30 Jun 2026: revenue $321.2M, net income $54.6MQuarter to 30 Jun 2026: revenue $321.2M, net income $54.6MQuarter to 30 Sep 2026: revenue $299.7M, net income $28.3MQuarter to 30 Sep 2026: revenue $299.7M, net income $28.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $321.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$299.7M$28.3M
30 Jun 2026$321.2M$54.6M
31 Mar 2026$311.4M$51.0M
31 Dec 2025$295.9M$38.0M
30 Sep 2025$286.6M$38.2M
30 Jun 2025$317.0M-$17.7M
31 Mar 2025$316.2M$22.6M
31 Dec 2024$297.0M$34.9M
30 Sep 2024$289.5M$33.6M
30 Jun 2024$306.1M$40.6M
31 Mar 2024$303.4M$49.1M
31 Dec 2023$272.6M$27.5M
30 Sep 2023$276.9M$51.0M
30 Jun 2023$301.3M$75.5M
31 Mar 2023$294.1M$70.2M
31 Dec 2022$271.6M$50.0M
30 Sep 2022$269.7M$89.6M
30 Jun 2022$288.2M$61.5M
31 Mar 2022$290.4M$60.7M
31 Dec 2021$269.3M$80.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.2B $1.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +0.9% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $172.0M $78.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.09 $0.49
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 65.8% 65.4% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 19.6% 9.0% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 14.0% 6.4% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 8.3% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $308.2M $224.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $350.0M $145.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $200.0M $300.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$150.0M (net cash) $155.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.09 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $13.79
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 66.4 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 9.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 9.2 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.3 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 0.44% 1.6%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Bio-TechneTECH (this company) $11.4B66.49.3+0.9%14.0%
RepligenRGEN $10.5Bloss13.0+14%-1.5%
Halozyme TherapeuticsHALO $10.4B21.55.8+45%26.9%
Kymera TherapeuticsKYMR $9.8Bloss96.3+134%-342%
Krystal BiotechKRYS $9.2B40.719.5+26%47.9%
VaxcytePCVX $8.8Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-1.4%

577 13F filers vs 585

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

154.4M shares held by 13F filers (30 Sep 2026) of 157.1M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.9%

7.7M shares sold short (30 Oct 2026) of 157.1M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.7

7.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.0%

7.6M shares sold short in the report before, 7.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

43%

43% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.6%

$299.7M vs $286.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+10%

$5.9M vs $5.4M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

16

16 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.3×

16 articles in the last 7 days; its usual week has 3.

Price $72.67 on 20 Nov 2026, +24% over 12 months (12-month range $43.30 to $72.84)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $437K in the last 12 months (the 12 months before: -$3.1M).
Revenue per quarter. Revenue $299.7M in the latest quarter, +4.6% on a year earlier.
Capital spending per quarter. Capital spending $5.9M in the latest quarter, +10% on a year earlier.
Institutional holders (13F filers). 577 13F filers reported holding it in the latest 13F quarter, +5.9% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
25 Jun 20268-K and other filingsDirector or officer change
25 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 2026Sharp changeShort interest spike: short interest spike, 12.4M vs usual 6.7M (2026-03-13); 2.0x the same period a year earlier
11 Feb 20268-K and other filingsDirector or officer change
11 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Mar 20258-K and other filingsDirector or officer change
5 Feb 20258-K and other filingsDirector or officer change
5 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Nov 20248-K and other filingsDirector or officer change
5 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 2024Sharp changeShort interest spike: short interest spike, 6.7M vs usual 3.4M (2024-05-15); 2.2x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 5.9M vs usual 3.4M (2024-04-30); 2.1x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 5.8M vs usual 3.4M (2024-04-15); 1.5x the same period a year earlier
30 Apr 20248-K and other filingsDirector or officer change
30 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Apr 2024Sharp changeShort interest spike: short interest spike, 5.3M vs usual 3.3M (2024-03-28); 2.2x the same period a year earlier
15 Apr 2024Sharp changeLobbying on a new issue: lobbying on a new issue: BUD (2024-03-31)
2 Apr 2024Sharp changeShort interest spike: short interest spike, 5.1M vs usual 3.2M (2024-03-15); 2.0x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 4.9M vs usual 3.0M (2023-12-29); 2.1x the same period a year earlier
16 Jan 2024Sharp changeLobbying on a new issue: lobbying on a new issue: AGR (2023-12-31)
16 Jan 2024Lobbying filingnew lobbying registration (SQUIRE PATTON BOGGS)
8 Jan 20248-K and other filingsDirector or officer change
2 Jan 2024Sharp changeShort interest spike: short interest spike, 5.0M vs usual 3.0M (2023-12-15); 2.1x the same period a year earlier
19 Oct 20238-K and other filingsDirector or officer change
19 Oct 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 May 2023Sharp changeShort interest spike: short interest spike, 3.0M vs usual 781K (2023-05-15); 5.4x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 2.8M vs usual 763K (2023-04-28); 4.8x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 3.7M vs usual 758K (2023-04-14); 5.4x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 2.4M vs usual 758K (2023-03-31); 2.8x the same period a year earlier
28 Mar 2023Sharp changeShort interest spike: short interest spike, 2.6M vs usual 758K (2023-03-15); 3.4x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 2.6M vs usual 727K (2023-02-28); 3.9x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 700K (2023-02-15); 4.2x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 2.7M vs usual 699K (2023-01-31); 5.2x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 2.3M vs usual 697K (2023-01-13); 4.7x the same period a year earlier
31 Jan 20238-K and other filingsDirector or officer change
31 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jan 2023Sharp changeShort interest spike: short interest spike, 2.4M vs usual 686K (2022-12-30); 4.9x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 2.4M vs usual 665K (2022-12-15); 5.1x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 2.4M vs usual 615K (2022-11-30); 5.5x the same period a year earlier
5 Aug 20228-K and other filingsDirector or officer change
5 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Apr 2022Sharp changeShort interest spike: short interest spike, 870K vs usual 439K (2022-03-31); 2.3x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 765K vs usual 434K (2022-03-15); 1.9x the same period a year earlier
22 Dec 20218-K and other filingsDirector or officer change
22 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: -$253K published
Month from 1 May 2022: $106K published
Month from 1 Jun 2022: -$2.4M published
Month from 1 Aug 2022: -$949K published
Month from 1 Dec 2022: -$677K published
Month from 1 Jun 2023: -$27K published
Month from 1 Jul 2023: -$7.1M published
Month from 1 Sep 2023: -$718K published
Month from 1 Mar 2024: -$801K published
Month from 1 May 2024: -$335K published
Month from 1 Aug 2024: -$1.2M published
Month from 1 Jan 2025: -$1.0M published
Month from 1 Feb 2025: -$123K published
Month from 1 Jun 2025: -$64K published
Month from 1 Aug 2025: -$1.9M published
Month from 1 Feb 2026: -$117K published
Month from 1 May 2026: -$320K published
Revenue per quarter
Quarter ended 31 Dec 2021: $269.3M, +20% on a year earlier; public on 8 Feb 2022
Quarter ended 31 Mar 2022: $290.4M, +19% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $288.2M, +11% on a year earlier; public on 25 Aug 2022
Quarter ended 30 Sep 2022: $269.7M, +4.6% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $271.6M, +0.9% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $294.1M, +1.3% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $301.3M, +4.5% on a year earlier; public on 24 Aug 2023
Quarter ended 30 Sep 2023: $276.9M, +2.7% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $272.6M, +0.4% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $303.4M, +3.2% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $306.1M, +1.6% on a year earlier; public on 23 Aug 2024
Quarter ended 30 Sep 2024: $289.5M, +4.5% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $297.0M, +9.0% on a year earlier; public on 7 Feb 2025
Quarter ended 31 Mar 2025: $316.2M, +4.2% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $317.0M, +3.5% on a year earlier; public on 23 Aug 2025
Quarter ended 30 Sep 2025: $286.6M, -1.0% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $295.9M, -0.4% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $311.4M, -1.5% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $321.2M, +1.3% on a year earlier; public on 25 Aug 2026
Quarter ended 30 Sep 2026: $299.7M, +4.6% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $10.2M, -11% on a year earlier; public on 8 Feb 2022
Quarter ended 31 Mar 2022: $15.1M, +42% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $13.6M, +20% on a year earlier; public on 25 Aug 2022
Quarter ended 30 Sep 2022: $9.6M, +57% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $6.1M, -40% on a year earlier; public on 8 Feb 2023
Quarter ended 31 Mar 2023: $11.7M, -22% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $10.8M, -20% on a year earlier; public on 24 Aug 2023
Quarter ended 30 Sep 2023: $13.6M, +42% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $14.9M, +143% on a year earlier; public on 8 Feb 2024
Quarter ended 31 Mar 2024: $16.4M, +40% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $18.0M, +66% on a year earlier; public on 23 Aug 2024
Quarter ended 30 Sep 2024: $9.2M, -33% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $6.8M, -54% on a year earlier; public on 7 Feb 2025
Quarter ended 31 Mar 2025: $10.1M, -38% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $4.9M, -73% on a year earlier; public on 23 Aug 2025
Quarter ended 30 Sep 2025: $5.4M, -42% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $5.9M, -13% on a year earlier; public on 5 Feb 2026
Quarter ended 31 Mar 2026: $9.1M, -10% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $8.5M, +73% on a year earlier; public on 25 Aug 2026
Quarter ended 30 Sep 2026: $5.9M, +10% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 507; public on 14 Feb 2022
31 Mar 2022 report: 516; public on 16 May 2022
30 Jun 2022 report: 516; public on 15 Aug 2022
30 Sep 2022 report: 485; public on 14 Nov 2022
31 Dec 2022 report: 493; public on 14 Feb 2023
31 Mar 2023 report: 513; public on 15 May 2023
30 Jun 2023 report: 485; public on 14 Aug 2023
30 Sep 2023 report: 486; public on 14 Nov 2023
31 Dec 2023 report: 493; public on 14 Feb 2024
31 Mar 2024 report: 527; public on 15 May 2024
30 Jun 2024 report: 541; public on 14 Aug 2024
30 Sep 2024 report: 523; public on 14 Nov 2024
31 Dec 2024 report: 551; public on 14 Feb 2025
31 Mar 2025 report: 555; public on 15 May 2025
30 Jun 2025 report: 525; public on 14 Aug 2025
30 Sep 2025 report: 545; public on 14 Nov 2025
31 Dec 2025 report: 562; public on 17 Feb 2026
31 Mar 2026 report: 571; public on 15 May 2026
30 Jun 2026 report: 585; public on 14 Aug 2026
30 Sep 2026 report: 577; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2024: $10K published
Quarter from 1 Apr 2024: $10K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $26.3M (30 Sep 2026), 1.1× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $437K in the last 12 months (the 12 months before: -$3.1M).
  • Revenue per quarter: Revenue $299.7M in the latest quarter, +4.6% on a year earlier.
  • Capital spending per quarter: Capital spending $5.9M in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 12 May 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 May 2026Amy E. HerrDirectorSellafter exercising options6,636$48.28$320KForm 4
19 Feb 2026Amy E. HerrDirectorSell1,976$59.11$117KForm 4
27 Aug 2025Robert Baumgartner VDirectorSellafter exercising options17,040$56.21$958KForm 4
27 Aug 2025Roeland NusseDirectorSellafter exercising options17,040$56.36$960KForm 4
11 Jun 2025Amy E. HerrDirectorSellafter exercising options1,280$49.77$64KForm 4
18 Feb 2025Amy E. HerrDirectorSellafter exercising options1,860$65.96$123KForm 4
29 Jan 2025Kim KeldermanChief Executive OfficerSellafter exercising options13,392$77.28$1.0MForm 4
12 Aug 2024Robert Baumgartner VDirectorSellafter exercising options16,000$72.10$1.2MForm 4

577 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 80 opened a position, 98 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.14.3M9.07%$1.0B+225K+1.6%
Vanguard Capital Management LLC10.3M6.53%$742.9M+32K+0.3%
HBK Investments L P7.7M4.92%$560.3M+907K+13%
Vanguard Portfolio Management LLC6.3M4.04%$460.1M-157K-2.4%
FIL Ltd6.3M3.99%$454.6M+6.3M1,589 times as many
State Street Corp6.0M3.85%$438.1M+66K+1.1%
Geode Capital Management, LLC5.4M3.46%$393.1M+80K+1.5%
Goldman Sachs Group Inc4.1M2.64%$300.3M-3.2M-44%
Millennium Management LLC4.1M2.60%$296.5M+3.1M+314%
Invesco Ltd.3.8M2.40%$273.6M-1.2M-24%

Company events

All 25 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
25 Jun 2026Director or officer change; Signed a major agreement8-K
11 Feb 2026Director or officer change8-K
4 Mar 2025Director or officer change8-K
5 Feb 2025Director or officer change8-K
5 Nov 2024Director or officer change8-K
30 Apr 2024Director or officer change8-K
8 Jan 2024Director or officer change8-K
19 Oct 2023Director or officer change8-K

Reported lobbying spend: $10K in Q1 2024, $10K in Q4 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
13 Nov 2023NewSquire Patton Boggsfor Bio-Techne CorporationContacts with House and Senate regarding USDA certification proceduresAgricultureFiling
12 Jul 2021EndedMichael Best Strategies LLCfor Bio-TechneNot statedFiling
1 Sep 2020NewMichael Best Strategies LLCfor Bio-TechneIssues relating to COVID-19Health issuesFiling

The 5 newest of 198 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Apr 2024confirmed

Confirmed across sources Lobbying and Short interest and volume

Bio-Techne (TECH): lobbying on a new issue, while it had 6.7M shares sold short in the 15 May 2024 report, 2.2× the same report last year. Two unrelated kinds of activity within 56 days.

  • Short interest and volume: Short interest spike, became public on 27 Mar 2024
  • Lobbying: Lobbying on a new issue, became public on 15 Apr 2024
  • Short interest and volume: Short interest spike, became public on 10 Apr 2024
  • Short interest and volume: Short interest spike, became public on 25 Apr 2024
  • Short interest and volume: Short interest spike, became public on 10 May 2024
  • Short interest and volume: Short interest spike, became public on 25 May 2024
2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M2024-05-15: 6.7M
The 15 May 2024 report against the 24 reports before it. this reportearliernormal: 3.4M
See the evidence (6 changes)

Short interest and volume: Short interest spike became public on 27 Mar 2024

Bio-Techne had 5.1M shares sold short in the 15 Mar 2024 report, 2.0× the same report last year.

This period
5.1M (the 15 Mar 2024 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
353K
How far from its usual level
+3.6
Same report last year
2.6M
History used
2,268 days
2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M
the 15 Mar 2024 report24 earlier reportsnormal: 3.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 15 Apr 2024

Bio-Techne lobbying on a new issue.

New
['BUD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12614581

Short interest and volume: Short interest spike became public on 10 Apr 2024

Bio-Techne had 5.3M shares sold short in the 28 Mar 2024 report, 2.2× the same report last year.

This period
5.3M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
365K
How far from its usual level
+3.8
Same report last year
2.4M
History used
2,281 days
2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M
the 28 Mar 2024 report24 earlier reportsnormal: 3.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Apr 2024

Bio-Techne had 5.8M shares sold short in the 15 Apr 2024 report, 1.5× the same report last year.

This period
5.8M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
376K
How far from its usual level
+4.3
Same report last year
3.7M
History used
2,299 days
2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M
the 15 Apr 2024 report24 earlier reportsnormal: 3.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2024

Bio-Techne had 5.9M shares sold short in the 30 Apr 2024 report, 2.1× the same report last year.

This period
5.9M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
400K
How far from its usual level
+4.3
Same report last year
2.8M
History used
2,314 days
2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M
the 30 Apr 2024 report24 earlier reportsnormal: 3.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 May 2024

Bio-Techne had 6.7M shares sold short in the 15 May 2024 report, 2.2× the same report last year.

This period
6.7M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
460K
How far from its usual level
+4.8
Same report last year
3.0M
History used
2,329 days
2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M2024-05-15: 6.7M
the 15 May 2024 report24 earlier reportsnormal: 3.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Jan 2024confirmed

Confirmed across sources Lobbying and Short interest and volume

Bio-Techne (TECH): had 5.0M shares sold short in the 15 Dec 2023 report, 2.1× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 14 days.

  • Short interest and volume: Short interest spike, became public on 28 Dec 2023
  • Lobbying: Lobbying on a new issue, became public on 16 Jan 2024
  • Short interest and volume: Short interest spike, became public on 11 Jan 2024
2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M
The 15 Dec 2023 report against the 24 reports before it. this reportearliernormal: 3.0M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 28 Dec 2023

Bio-Techne had 5.0M shares sold short in the 15 Dec 2023 report, 2.1× the same report last year.

This period
5.0M (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
3.0M
Typical spread (median absolute deviation)
330K
How far from its usual level
+4.2
Same report last year
2.4M
History used
2,177 days
2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M
the 15 Dec 2023 report24 earlier reportsnormal: 3.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: Lobbying on a new issue became public on 16 Jan 2024

Bio-Techne lobbying on a new issue.

New
['AGR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12615656

Short interest and volume: Short interest spike became public on 11 Jan 2024

Bio-Techne had 4.9M shares sold short in the 29 Dec 2023 report, 2.1× the same report last year.

This period
4.9M (the 29 Dec 2023 report)
Normal report (median of 24 earlier)
3.0M
Typical spread (median absolute deviation)
343K
How far from its usual level
+3.7
Same report last year
2.4M
History used
2,191 days
2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M
the 29 Dec 2023 report24 earlier reportsnormal: 3.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

31 Aug 2021confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Bio-Techne (TECH): saw 74 13F filers open a new position in the quarter ended 30 Jun 2021, 1.2× the same quarter last year, while it reported revenue of $259.0M for the quarter ended 30 Jun 2021, 1.5× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 16 Aug 2021
  • Financials: Quarterly revenue change, became public on 31 Aug 2021
2019-06-30: 462019-09-30: 272019-12-31: 482020-03-31: 392020-06-30: 612020-09-30: 472020-12-31: 482021-03-31: 612021-06-30: 74
The quarter ended 30 Jun 2021 against the 8 quarters before it. this quarterearliernormal: 47.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 16 Aug 2021

Bio-Techne saw 74 13F filers open a new position in the quarter ended 30 Jun 2021, 1.2× the same quarter last year.

This period
74 (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
47.5
Typical spread (median absolute deviation)
5
How far from its usual level
+3.6
Same quarter last year
61
History used
2,648 days
2019-06-30: 462019-09-30: 272019-12-31: 482020-03-31: 392020-06-30: 612020-09-30: 472020-12-31: 482021-03-31: 612021-06-30: 74
the quarter ended 30 Jun 20218 earlier quartersnormal: 47.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly revenue change became public on 31 Aug 2021

Bio-Techne reported revenue of $259.0M for the quarter ended 30 Jun 2021, 1.5× the same quarter last year.

This period
$259.0M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$193.2M
Typical spread (median absolute deviation)
$10.5M
How far from its usual level
+3.4
Same quarter last year
$175.8M
History used
4,291 days
2019-06-30: $191.7M2019-09-30: $183.2M2019-12-31: $184.9M2020-03-31: $194.7M2020-06-30: $175.8M2020-09-30: $204.2M2020-12-31: $224.3M2021-03-31: $243.6M2021-06-30: $259.0M
the quarter ended 30 Jun 20218 earlier quartersnormal: $193.2M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 25 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 25 Jun 2026Filings record

    Director or officer change

  3. 25 Mar 2026Short interest and volume change

    had 12.4M shares sold short in the 13 Mar 2026 report, 2.0× the same report last year.

    Same report last year: 6.3M; its normal report is 6.7M.

    See the evidence
    This period
    12.4M (the 13 Mar 2026 report)
    Normal report (median of 24 earlier)
    6.7M
    Typical spread (median absolute deviation)
    908K
    How far from its usual level
    +4.2
    Same report last year
    6.3M
    History used
    2,996 days
    2025-03-14: 6.3M2025-03-31: 6.1M2025-04-15: 6.5M2025-04-30: 6.5M2025-05-15: 7.2M2025-05-30: 7.5M2025-06-13: 6.1M2025-06-30: 6.3M2025-07-15: 6.5M2025-07-31: 6.3M2025-08-15: 5.8M2025-08-29: 5.1M2025-09-15: 5.3M2025-09-30: 5.4M2025-10-15: 6.9M2025-10-31: 7.6M2025-11-14: 9.3M2025-11-28: 9.3M2025-12-15: 9.4M2025-12-31: 10.0M2026-01-15: 10.4M2026-01-30: 9.8M2026-02-13: 11.3M2026-02-27: 10.6M2026-03-13: 12.4M
    the 13 Mar 2026 report24 earlier reportsnormal: 6.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 11 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 11 Feb 2026Filings record

    Director or officer change

  6. 4 Mar 2025Filings record

    Director or officer change

  7. 5 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 5 Feb 2025Filings record

    Director or officer change

  9. 5 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 5 Nov 2024Filings record

    Director or officer change

  11. 25 May 2024Short interest and volume change

    had 6.7M shares sold short in the 15 May 2024 report, 2.2× the same report last year.

    Same report last year: 3.0M; its normal report is 3.4M.

    See the evidence
    This period
    6.7M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    460K
    How far from its usual level
    +4.8
    Same report last year
    3.0M
    History used
    2,329 days
    2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M2024-05-15: 6.7M
    the 15 May 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 10 May 2024Short interest and volume change

    had 5.9M shares sold short in the 30 Apr 2024 report, 2.1× the same report last year.

    Same report last year: 2.8M; its normal report is 3.4M.

    See the evidence
    This period
    5.9M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    400K
    How far from its usual level
    +4.3
    Same report last year
    2.8M
    History used
    2,314 days
    2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M
    the 30 Apr 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 30 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 30 Apr 2024Filings record

    Director or officer change

  15. 25 Apr 2024Short interest and volume change

    had 5.8M shares sold short in the 15 Apr 2024 report, 1.5× the same report last year.

    Same report last year: 3.7M; its normal report is 3.4M.

    See the evidence
    This period
    5.8M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    376K
    How far from its usual level
    +4.3
    Same report last year
    3.7M
    History used
    2,299 days
    2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M
    the 15 Apr 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 15 Apr 2024several at once

    lobbying on a new issue, while it had 6.7M shares sold short in the 15 May 2024 report, 2.2× the same report last year. Two unrelated kinds of activity within 56 days.

    See the evidence (6 changes)

    Short interest and volume: Short interest spike became public on 27 Mar 2024

    Bio-Techne had 5.1M shares sold short in the 15 Mar 2024 report, 2.0× the same report last year.

    This period
    5.1M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +3.6
    Same report last year
    2.6M
    History used
    2,268 days
    2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M
    the 15 Mar 2024 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 15 Apr 2024

    Bio-Techne lobbying on a new issue.

    New
    ['BUD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12614581

    Short interest and volume: Short interest spike became public on 10 Apr 2024

    Bio-Techne had 5.3M shares sold short in the 28 Mar 2024 report, 2.2× the same report last year.

    This period
    5.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +3.8
    Same report last year
    2.4M
    History used
    2,281 days
    2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Apr 2024

    Bio-Techne had 5.8M shares sold short in the 15 Apr 2024 report, 1.5× the same report last year.

    This period
    5.8M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    376K
    How far from its usual level
    +4.3
    Same report last year
    3.7M
    History used
    2,299 days
    2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M
    the 15 Apr 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 May 2024

    Bio-Techne had 5.9M shares sold short in the 30 Apr 2024 report, 2.1× the same report last year.

    This period
    5.9M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    400K
    How far from its usual level
    +4.3
    Same report last year
    2.8M
    History used
    2,314 days
    2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M
    the 30 Apr 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 May 2024

    Bio-Techne had 6.7M shares sold short in the 15 May 2024 report, 2.2× the same report last year.

    This period
    6.7M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    3.4M
    Typical spread (median absolute deviation)
    460K
    How far from its usual level
    +4.8
    Same report last year
    3.0M
    History used
    2,329 days
    2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M2024-04-15: 5.8M2024-04-30: 5.9M2024-05-15: 6.7M
    the 15 May 2024 report24 earlier reportsnormal: 3.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  17. 15 Apr 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['BUD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12614581
  18. 10 Apr 2024Short interest and volume change

    had 5.3M shares sold short in the 28 Mar 2024 report, 2.2× the same report last year.

    Same report last year: 2.4M; its normal report is 3.3M.

    See the evidence
    This period
    5.3M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.3M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +3.8
    Same report last year
    2.4M
    History used
    2,281 days
    2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M2024-03-28: 5.3M
    the 28 Mar 2024 report24 earlier reportsnormal: 3.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 27 Mar 2024Short interest and volume change

    had 5.1M shares sold short in the 15 Mar 2024 report, 2.0× the same report last year.

    Same report last year: 2.6M; its normal report is 3.2M.

    See the evidence
    This period
    5.1M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +3.6
    Same report last year
    2.6M
    History used
    2,268 days
    2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M2024-01-12: 4.0M2024-01-31: 3.3M2024-02-15: 4.7M2024-02-29: 4.6M2024-03-15: 5.1M
    the 15 Mar 2024 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 16 Jan 2024several at once

    had 5.0M shares sold short in the 15 Dec 2023 report, 2.1× the same report last year, while it lobbying on a new issue. Two unrelated kinds of activity within 14 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 28 Dec 2023

    Bio-Techne had 5.0M shares sold short in the 15 Dec 2023 report, 2.1× the same report last year.

    This period
    5.0M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    330K
    How far from its usual level
    +4.2
    Same report last year
    2.4M
    History used
    2,177 days
    2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M
    the 15 Dec 2023 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Lobbying: Lobbying on a new issue became public on 16 Jan 2024

    Bio-Techne lobbying on a new issue.

    New
    ['AGR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12615656

    Short interest and volume: Short interest spike became public on 11 Jan 2024

    Bio-Techne had 4.9M shares sold short in the 29 Dec 2023 report, 2.1× the same report last year.

    This period
    4.9M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    343K
    How far from its usual level
    +3.7
    Same report last year
    2.4M
    History used
    2,191 days
    2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M
    the 29 Dec 2023 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  21. 16 Jan 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['AGR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12615656
  22. 16 Jan 2024Lobbying record

    BIO-TECHNE CORPORATION: new lobbying registration (SQUIRE PATTON BOGGS) (dated 13 Nov 2023)

  23. 11 Jan 2024Short interest and volume change

    had 4.9M shares sold short in the 29 Dec 2023 report, 2.1× the same report last year.

    Same report last year: 2.4M; its normal report is 3.0M.

    See the evidence
    This period
    4.9M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    343K
    How far from its usual level
    +3.7
    Same report last year
    2.4M
    History used
    2,191 days
    2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M2023-12-29: 4.9M
    the 29 Dec 2023 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 8 Jan 2024Filings record

    Director or officer change

  25. 28 Dec 2023Short interest and volume change

    had 5.0M shares sold short in the 15 Dec 2023 report, 2.1× the same report last year.

    Same report last year: 2.4M; its normal report is 3.0M.

    See the evidence
    This period
    5.0M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    3.0M
    Typical spread (median absolute deviation)
    330K
    How far from its usual level
    +4.2
    Same report last year
    2.4M
    History used
    2,177 days
    2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M2023-05-31: 3.0M2023-06-15: 3.0M2023-06-30: 2.8M2023-07-14: 3.1M2023-07-31: 2.9M2023-08-15: 3.1M2023-08-31: 3.1M2023-09-15: 3.4M2023-09-29: 3.7M2023-10-13: 3.4M2023-10-31: 3.2M2023-11-15: 2.9M2023-11-30: 3.6M2023-12-15: 5.0M
    the 15 Dec 2023 report24 earlier reportsnormal: 3.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 19 Oct 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 19 Oct 2023Filings record

    Director or officer change

  28. 25 May 2023Short interest and volume change

    had 3.0M shares sold short in the 15 May 2023 report, 5.4× the same report last year.

    Same report last year: 558K; its normal report is 781K.

    See the evidence
    This period
    3.0M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    781K
    Typical spread (median absolute deviation)
    226K
    How far from its usual level
    +6.6
    Same report last year
    558K
    History used
    1,963 days
    2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M2023-05-15: 3.0M
    the 15 May 2023 report24 earlier reportsnormal: 781K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 May 2023Short interest and volume change

    had 2.8M shares sold short in the 28 Apr 2023 report, 4.8× the same report last year.

    Same report last year: 577K; its normal report is 763K.

    See the evidence
    This period
    2.8M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    763K
    Typical spread (median absolute deviation)
    204K
    How far from its usual level
    +6.7
    Same report last year
    577K
    History used
    1,946 days
    2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M2023-04-28: 2.8M
    the 28 Apr 2023 report24 earlier reportsnormal: 763K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 26 Apr 2023Short interest and volume change

    had 3.7M shares sold short in the 14 Apr 2023 report, 5.4× the same report last year.

    Same report last year: 700K; its normal report is 758K.

    See the evidence
    This period
    3.7M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    758K
    Typical spread (median absolute deviation)
    194K
    How far from its usual level
    +10.4
    Same report last year
    700K
    History used
    1,932 days
    2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M2023-04-14: 3.7M
    the 14 Apr 2023 report24 earlier reportsnormal: 758K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 13 Apr 2023Short interest and volume change

    had 2.4M shares sold short in the 31 Mar 2023 report, 2.8× the same report last year.

    Same report last year: 870K; its normal report is 758K.

    See the evidence
    This period
    2.4M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    758K
    Typical spread (median absolute deviation)
    187K
    How far from its usual level
    +6.0
    Same report last year
    870K
    History used
    1,918 days
    2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M2023-03-31: 2.4M
    the 31 Mar 2023 report24 earlier reportsnormal: 758K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 25 Mar 2023Short interest and volume change

    had 2.6M shares sold short in the 15 Mar 2023 report, 3.4× the same report last year.

    Same report last year: 765K; its normal report is 758K.

    See the evidence
    This period
    2.6M (the 15 Mar 2023 report)
    Normal report (median of 24 earlier)
    758K
    Typical spread (median absolute deviation)
    182K
    How far from its usual level
    +6.8
    Same report last year
    765K
    History used
    1,902 days
    2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M2023-03-15: 2.6M
    the 15 Mar 2023 report24 earlier reportsnormal: 758K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 10 Mar 2023Short interest and volume change

    had 2.6M shares sold short in the 28 Feb 2023 report, 3.9× the same report last year.

    Same report last year: 653K; its normal report is 727K.

    See the evidence
    This period
    2.6M (the 28 Feb 2023 report)
    Normal report (median of 24 earlier)
    727K
    Typical spread (median absolute deviation)
    147K
    How far from its usual level
    +8.4
    Same report last year
    653K
    History used
    1,887 days
    2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M2023-02-28: 2.6M
    the 28 Feb 2023 report24 earlier reportsnormal: 727K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 28 Feb 2023Short interest and volume change

    had 2.2M shares sold short in the 15 Feb 2023 report, 4.2× the same report last year.

    Same report last year: 523K; its normal report is 700K.

    See the evidence
    This period
    2.2M (the 15 Feb 2023 report)
    Normal report (median of 24 earlier)
    700K
    Typical spread (median absolute deviation)
    125K
    How far from its usual level
    +8.1
    Same report last year
    523K
    History used
    1,874 days
    2022-02-15: 523K2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M2023-02-15: 2.2M
    the 15 Feb 2023 report24 earlier reportsnormal: 700K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 10 Feb 2023Short interest and volume change

    had 2.7M shares sold short in the 31 Jan 2023 report, 5.2× the same report last year.

    Same report last year: 519K; its normal report is 699K.

    See the evidence
    This period
    2.7M (the 31 Jan 2023 report)
    Normal report (median of 24 earlier)
    699K
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +11.1
    Same report last year
    519K
    History used
    1,859 days
    2022-01-31: 519K2022-02-15: 523K2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M2023-01-31: 2.7M
    the 31 Jan 2023 report24 earlier reportsnormal: 699K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 31 Jan 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 31 Jan 2023Filings record

    Director or officer change

  38. 26 Jan 2023Short interest and volume change

    had 2.3M shares sold short in the 13 Jan 2023 report, 4.7× the same report last year.

    Same report last year: 485K; its normal report is 697K.

    See the evidence
    This period
    2.3M (the 13 Jan 2023 report)
    Normal report (median of 24 earlier)
    697K
    Typical spread (median absolute deviation)
    121K
    How far from its usual level
    +8.9
    Same report last year
    485K
    History used
    1,841 days
    2022-01-14: 485K2022-01-31: 519K2022-02-15: 523K2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M2023-01-13: 2.3M
    the 13 Jan 2023 report24 earlier reportsnormal: 697K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 12 Jan 2023Short interest and volume change

    had 2.4M shares sold short in the 30 Dec 2022 report, 4.9× the same report last year.

    Same report last year: 481K; its normal report is 686K.

    See the evidence
    This period
    2.4M (the 30 Dec 2022 report)
    Normal report (median of 24 earlier)
    686K
    Typical spread (median absolute deviation)
    111K
    How far from its usual level
    +10.2
    Same report last year
    481K
    History used
    1,827 days
    2021-12-15: 481K2022-01-14: 485K2022-01-31: 519K2022-02-15: 523K2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M2022-12-30: 2.4M
    the 30 Dec 2022 report24 earlier reportsnormal: 686K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 28 Dec 2022Short interest and volume change

    had 2.4M shares sold short in the 15 Dec 2022 report, 5.1× the same report last year.

    Same report last year: 481K; its normal report is 665K.

    See the evidence
    This period
    2.4M (the 15 Dec 2022 report)
    Normal report (median of 24 earlier)
    665K
    Typical spread (median absolute deviation)
    101K
    How far from its usual level
    +12.0
    Same report last year
    481K
    History used
    1,812 days
    2021-11-30: 432K2021-12-15: 481K2022-01-14: 485K2022-01-31: 519K2022-02-15: 523K2022-02-28: 653K2022-03-15: 765K2022-03-31: 870K2022-04-14: 700K2022-04-29: 577K2022-05-13: 558K2022-05-31: 567K2022-06-15: 575K2022-06-30: 797K2022-07-15: 765K2022-07-29: 754K2022-08-15: 552K2022-08-31: 560K2022-09-15: 701K2022-09-30: 698K2022-10-14: 676K2022-10-31: 696K2022-11-15: 761K2022-11-30: 2.4M2022-12-15: 2.4M
    the 15 Dec 2022 report24 earlier reportsnormal: 665K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.

Not listed: 268 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000842023
Ticker
TECH
Domain
bio-techne.com
Employer name
advanced cell diagnostics
Hq location
MN|MINNEAPOLIS| (1 unverified)
Lobbying client
bio techne
Name
Advanced Cell Diagnostics, Inc, Asuragen, Inc, Bio-Techne China Co. Ltd, Bio-Techne Corp. and 6 more
Wikidata
Q19873469
Wikipedia
Bio-Techne
  • DOL H-1B labor condition applications and PERM certifications1 data point27 Jul 2026 to 27 Jul 2026
  • Federal lobbying disclosures (LDA)3 records, 36 data points1 Sep 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 459 data points31 Mar 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)167 records2 Feb 2016 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1267 data points30 Jun 2008 to 2 Nov 2026
  • SEC Form 4 insider transactions122 records, 440 data points8 Feb 2016 to 12 May 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026